Drug intelligence / Profile preview

BEL-X-HG

Development stage: Discontinued
Lead developer: BELX Bio-Pharmaceutical Corporation
Modality: Small Molecules
Administration: Oral

Overview

BEL-X-HG is an orally available, botanically-based agent developed by Belx Bio-Pharmaceutical (Taiwan) Corporation for its potential antineoplastic (anticancer) activity. Upon oral administration, the components in BEL-X-HG may exert cytotoxic effects on tumor cells, potentially leading to antitumor activity. The drug was primarily investigated for use in patients with advanced refractory solid malignancies (advanced cancers that do not respond to standard treatments). Clinical development included a Phase 1 open-label dose escalation and extension study aimed at evaluating safety, tolerability, and preliminary efficacy in this patient population. Clinical development has been discontinued.

Other names: BEL-X

Beyond the preview

Go deeper on BEL-X-HG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEL-X-HG.

Explore the full profile